<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362140">
  <stage>Registered</stage>
  <submitdate>22/02/2012</submitdate>
  <approvaldate>24/02/2012</approvaldate>
  <actrnumber>ACTRN12612000238875</actrnumber>
  <trial_identification>
    <studytitle>Reduction of contrast induced nephropathy (CIN) in patients requiring a percutaneous coronary intervention procedure and have chronic renal failure.</studytitle>
    <scientifictitle>Multi-centre, single arm study to evaluate performance and safety of the CINCOR contrast media removal system in chronic renal disease patients requiring a percutaneous coronary intervention procedure.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TP-6201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cardiovascular disease in patients with chronic kidney disease.</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>CINCOR contrast removal system removes contrast from the circulatory system before it can reach the kidneys. The system uses a canula inserted into the circulatory system that removes contrast media. The procedure occurs at the same time as the percutaneous coronary procedure.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Device performance, measured by analysing successful use of the system and amount of contrast removed from the participant.</outcome>
      <timepoint>Day of surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Device safety, assessed by analysing adverse events. Adverse events of interest include bleeding, myocardial infarction, dialysis and heart arrhythmias. Adverse events rates will be compared with rates of previous clinical trials conducted on the CINCOR system and rates experienced in percutaneous coronary intervention procedures.</outcome>
      <timepoint>24 hours, 4 days and 30 days post percutaneous coronary procedure.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Chronic renal disease and requires a percutaneous coronary intervention procedure.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Not eligable for percutaneous coronary procedure or has an allergy to contrast media, unable/unwilling to provide consent, is pregnant.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Participants are screened for eligibility based on available clinical measurements. If eligible, participants are invited to participate in the study and asked to provide informed consent. All participants are allocated to the study intervention.</concealment>
    <sequence>Not applicable.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>None.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>22/02/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3004</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Osprey Medical Pty Ltd</primarysponsorname>
    <primarysponsoraddress>c/o CM Capital Investments Pty Ltd
Level 4, 167 Eagle Street 
Brisbane, QLD, 4000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Osprey Medical Pty Ltd</fundingname>
      <fundingaddress>c/o CM Capital Investments Pty Ltd
Level 4, 167 Eagle Street 
Brisbane, QLD, 4000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to help reduce the incidence of contrast induced nephropathy in patients who have impaired kidney function and required a purcutaneous coronary intervention procedure (e.g. stent) due to cardiovascular disease.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital
Commercial Road
Prahran, VIC, 3004</ethicaddress>
      <ethicapprovaldate>12/01/2012</ethicapprovaldate>
      <hrec>1/11/0371</hrec>
      <ethicsubmitdate>27/10/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dan Mans</name>
      <address>7600 Executive Drive
Eden Praire, MN, 55344</address>
      <phone>+1 952 955 8236</phone>
      <fax>+1 952 955 8171</fax>
      <email>dmans@ospreymed.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dan Mans</name>
      <address>7600 Executive Drive
Eden Praire, MN, 55344</address>
      <phone>+1 952 955 8236</phone>
      <fax>+1 952 955 8171</fax>
      <email>dmans@ospreymed.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>